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Heike Scheithauer1, Claus Belka1, Kirsten Lauber1* and Udo S Gaipl2The major objective of radiotherapy (RT) in the context
of cancer treatment is the achievement of local tumor
control. Traditionally, this is considered to be mediated
by the induction of DNA damage, resulting in tumor cell
death and abrogated clonogenic survival [1]. However, it
has become more and more evident that distinct irradi-
ation regimes as well as selected doses of ionizing
radiation, and particularly the combination with immu-
notherapeutic approaches can induce or modulate sys-
temic immune responses, which contribute to tumor
control or inflammatory side effects, respectively. Locally
administered RT can instigate systemic, abscopal, or
'out-of-field' effects, and meanwhile it is well acknowl-
edged that DNA damage responses and immunological
events, including anti-tumor immune mechanisms and
inflammatory reactions are interconnected. The Special
Topic Immunological aspects of radiotherapy aims to
introduce radiation oncologists and researchers in the
field of molecular and cellular oncology to the manifold
aspects of how RT impacts on immune modulation, and
how the combination with targeted therapies and se-
lected immunotherapeutic strategies can result in im-
proved local and systemic tumor control via the
stimulation of anti-tumor immune responses. Focus is
set on the immunological effects of different irradiation
regimes and doses, synergistic effects between RT and
immunotherapy with natural killer cells or mRNA-based
vaccines, and finally on immunological normal tissue
reactions.
The interaction of monocytes and dying breast cancer
cells that have been subjected to different irradiation re-
gimes is addressed in the study by Hennel et al. [2]. The
authors characterize the type and the extent of cell death
induced by fractionated and ablative radiotherapeutic re-
gimes as well as the impact on the release of danger sig-
nals and monocyte attraction factors by dying breast
cancer cells. In essence, they describe that the irradiation
regime as well as the p53 and hormone receptor status* Correspondence: kirsten.lauber@med.uni-muenchen.de
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article, unless otherwise stated.govern the cell death response and subsequent mono-
cyte recruitment. Whereas fast proliferating, p53 mu-
tant, hormone receptor negative breast cancer cells
predominantly underwent primary necrosis upon abla-
tive irradiation at a single dose of 20 Gy, p53 wildtype
breast cancer cells revealed a multi-faceted response of
apoptosis, primary/secondary necrosis, and senescence.
Compared to fractionated irradiation at daily doses of
2 Gy, a much stronger cellular response in terms of
apoptosis, necrosis and senescence induction was
achieved by ablative irradiation. Importantly, necrotically
dying, p53 mutant, hormone receptor negative breast
cancer cells released apyrase-sensitive nucleotides - well-
known danger signals, which stimulated monocyte che-
mokinesis. In p53 wildtype, hormone receptor positive
cells this was hampered by the upregulation of the surface
ectonucleotidase CD39. Given that the intra-tumoral re-
cruitment of monocytes, their differentiation into antigen-
presenting cells, the capture of tumor antigens, and the
subsequent trafficking into tumor-draining lymph nodes
constitute initial and essential steps for the priming of
adaptive anti-tumor immune responses [3], the authors
conclude that especially for fast proliferating, hormone re-
ceptor negative, p53 mutant breast cancer ablative RT
might be beneficial. Future studies have to clarify, whether
the cascade of targeted necrosis induction, nucleotide re-
lease, and monocyte recruitment indeed can trigger the
priming of adaptive anti-tumor immunity in the context
of ablative radiotherapy [4].
The type of cell death response and concomitant dan-
ger signal release is also in the focus of the study by
Rubner et al. [5]. Using glioblastoma cell lines with dif-
ferent p53 and O6-methylguanine DNA methyltransfer-
ase (MGMT) expression status, the authors examine the
induction of glioblastoma cell death upon fractionated
RT at daily doses of 2 Gy alone or in combination with
clinically relevant concentrations of temozolomide
(TMZ) and/or the histone deacetylase (HDAC) inhibitor
valproic acid (VPA). As to be expected, p53 mutant,
MGMT expressing glioblastoma cells were more resist-
ant to fractionated RT +/- TMZ or VPA treatment and
showed increased clonogenic survival compared to p53ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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exhibit improved MGMT-mediated DNA damage repair
and compromised p53-dependent cell death and senes-
cence mechanisms [6]. Along the same lines, TMZ-
induced G2 cell cycle arrest was only observed in MGMT
negative cells with wildtype p53, and RT-induced G2 cell
cycle arrest was much more pronounced than in p53 mu-
tant, MGMT positive cell lines. Importantly, fractionated
RT was the main stimulus for apoptosis as well as necrosis
induction with concomitant release of the danger signals
heat-shock protein 70 (Hsp70) and high-mobility group
protein B1 (HMGB1) in p53 mutant, MGMT expressing
cells. Correspondingly, the authors conclude that espe-
cially in p53 mutant, MGMT positive glioblastoma frac-
tionated RT and not chemotherapy with TMZ or VPA
governs cell death induction and release of danger signals.
Both might be relevant for shaping an immunogenic
tumor microenvironment necessary for the induction of
systemic anti-tumor immunity, and future research has to
focus on how RT might contribute to the success of multi-
modal immunotherapeutic approaches for glioblastoma
multiforme [7].
The danger signal Hsp70 has been shown to activate
dendritic cells (DC) as well as natural killer (NK) cells,
and tumor cells are known to upregulate the expression
of this chaperone, since they experience a sort of consti-
tutive proteotoxic stress due to an overall increase in
protein synthesis and the overexpression of various mu-
tant oncoproteins [8]. Hsp70 might also be exposed on
the tumor cell surface, and thus appears to be a promis-
ing tumor biomarker as well as a potential target for
tumor therapy. Besides monitoring local responses by
analyzing Hsp70 in tumor biopsies, systemic effects
might be followed up by determining the serum concen-
tration of released Hsp70. This issue is addressed by the
study of Gehrmann et al. in the context of adjuvant RT
in patients with head and neck squamous cell carcinoma
(SCCHN) [9]. In 22 out of 23 single cell suspensions of
tumor biopsies, Hsp70 membrane expression was in-
creased compared to normal tissue cells. Tumors with
low and high Hsp70 expression levels were identified,
and the serum concentrations of Hsp70 before tumor re-
section were elevated in all patients compared to healthy
donors. During adjuvant RT, serum Hsp70 levels in-
creased up to 6 weeks after tumor excision and declined
afterwards to levels similar to those before RT. With a
timely delay, elevated anti-Hsp70 antibody titers were
observed in patients' sera. Importantly, Hsp70 and anti-
Hsp70 antibody serum levels correlated with the tumor
volume before therapy. Analyses of activation markers
on peripheral blood NK cells revealed an increase in the
expression densities of NKG2D, but not CD56, CD94,
nor NKp44 throughout the monitoring period. In sum-
mary, the authors propose the serum level of Hsp70 as abiomarker for tumor detection and RT monitoring in
SCCHN, whose applicability has to be evaluated in fur-
ther studies [10].
Son et al. addressed the question if and how RT alone
or in combination with HDAC inhibition alters the ex-
pression of NKG2D ligands in non-small cell lung can-
cer (NSCLC) cell lines. NKG2D is an activating NK cell
receptor, and the induction of NKG2D ligands in cancer
cells is known to be regulated by histone acetylation and -
at least in part - by the Atm (Ataxia Telangiectasia
Mutated protein)/Atr (Ataxia Telangiectasia and Rad3-
related protein) pathway, underscoring once more the
connection between DNA damage responses and immune
reactions [11]. While HDAC inhibition increased the ex-
pression of several NKG2D ligands, including MICA and
ULBP3, on the mRNA as well as on the surface protein
level, RT at a single dose of 8, 16, or 24 Gy did so only on
the surface protein level. Importantly, the combination of
RT and HDAC inhibition stimulated a supra-additive ele-
vation of NKG2D ligands on the tumor cell surface, which
was paralleled by a highly increased sensitivity towards
NK cell-mediated lysis. HDAC inhibitor-dependent induc-
tion of NKG2D ligand mRNA was not affected by Atm/
Atr inhibition, but RT-induced upregulation of NKG2D
surface expression was significantly impaired. The authors
conclude that the expression of NKG2D ligands is orches-
trated on multiple levels, and that the synergistic upregu-
lation observed by the combination of RT with HDAC
inhibition might be utilized for the improvement of NK
cell-based therapies in NSCLC with functional Atm/Atr
signaling [12].
An in vivo evaluation of the synergism between RT
and mRNA-based vaccination for the treatment of estab-
lished tumors is presented in the study by Fotin-Mleczek
et al. [13]. Vaccination strategies alone commonly fail to
eradicate large tumors due to the numerous immune eva-
sion mechanisms established tumors have acquired [14].
In this regard, RT is a highly promising 'partner' for com-
bined modality approaches, since it locally destroys the
tumor, can induce an immunostimulatory tumor micro-
environment, and systemically spares the immune system
(in contrast to chemotherapy). Fotin-Mleczek and co-
workers employed this concept for RT +/- vaccination
with OVA or EGFR mRNA of heterotopically trans-
planted, highly immunogenic E.G7-ovalbumin(OVA)
lymphoma or poorly immunogenic Lewis lung carcinoma
(LLC), respectively. In both model systems combined
radio-immunotherapy revealed strong synergistic anti-
tumor effects as displayed by potently delayed tumor
growth or even complete tumor eradication, while the
single treatments had only moderate or hardly detectable
effects. Of note, completely responding E.G7-OVA lymph-
oma carrying mice even survived subsequent re-challenge
with parental, OVA-negative EL-4 cells suggesting that the
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epitope spreading. Transcriptome analyses of the E.G7-
OVA lymphoma model revealed a unique gene signature
in the radio-immunotherapy group involving downregula-
tion of tumor associated genes and upregulation of genes
mediating tumor suppression. Characterization of infiltrat-
ing immune cells in the LLC model showed that the com-
bined treatment specifically stimulated an increase in
tumor infiltrating CD4+ and CD8+ T cells as well as NKT
cells, which was not detected in the single treatment
groups. The authors conclude that local RT is capable of
sculpting an immunogenic tumor microenvironment,
which renders even poorly immunogenic tumors suscep-
tible for mRNA-based vaccination leading to long lasting
anti-tumor immune memory and even epitope spreading.
Further mechanistic analyses are required to elucidate the
underlying mechanisms, but a comparable form of epitope
drift has already been observed in clinical phase II/III tri-
als with a poxviral vaccine encoding PSA in combination
with RT for prostate cancer [15].
Apart from modulating intended, anti-tumor-directed
immune effects, RT can stimulate unwanted, immune
cell-driven, adverse effects. Pneumonitis and lung fibro-
sis are examples of such dose-limiting side effects, which
are observed in the context of thorax RT, and whose
underlying mechanisms are so far barely understood
[16]. Wirsdörfer et al. examined the presence and/or in-
filtration of distinct immune cell subsets in different or-
gans upon thorax irradiation of C57BL/6 mice [17]. The
authors report that irradiation-induced pneumonitis was
associated with a characteristic time course of local and
systemic changes within the T cell compartment. Upon
single thorax irradiation at 15 Gy, a transient decrease in
systemic CD4+ T cell counts and a long-lasting decrease
in CD8+ T cells within peripheral lymphoid organs were
observed. Furthermore, the early phase of irradiation-
induced pneumonitis was paralleled by a local (lung)
and systemic (spleen, cervical lymph nodes), but transi-
ent accumulation of CD4 + FoxP3+ regulatory T cells
(Treg). These Treg exhibited immunosuppressive func-
tion as could be expected from the observed surface ex-
pression of immunosuppressive CD73, CTLA-4, and
CD103. The authors speculate that the accumulation of
Treg during early pneumonitis is due to their increased
survival after irradiation compared to effector T cells.
Treg might contribute to the control of irradiation-
induced pneumonitis and limit inflammation-associated
lung damage. Hence, it remains to be elucidated,
whether irradiation-induced pneumonitis exacerbates if
Treg function is impaired, and whether this can be
therapeutically addressed in the future.
RT can also exert immunosuppressive functions. This
is particularly observed in the low dose range, and is
exploited therapeutically in the context of acute andchronic inflammatory diseases [18]. Accumulating evi-
dence suggests that modulation of endothelial cells (EC),
lymphocytes, macrophages, and granulocytes is key for
the anti-inflammatory effects of low dose radiotherapy
(LD-RT). Interestingly, the observed immunomodulatory
consequences of LD-RT display a non-linear dose re-
sponse relationship, which is a central characteristic of
bystander effects induced by ionizing irradiation and
which is attributed to the involvement of multiple mo-
lecular mechanisms that may be instigated at various
threshold doses. The study presented by Large et al. ad-
dresses the connection between dampening effects of
LD-RT on activated EC, production of reactive oxygen
species (ROS), and DNA damage repair [19]. The au-
thors report that one day after irradiation of TNF-
stimulated EC at 0.5 Gy, but not at 0.3 nor 0.7 Gy,
increased numbers of residual γH2AX foci were de-
tected. Irrespective of TNF stimulation, this was accom-
panied by reduced expression levels and enzymatic
activity of superoxide dismutase (SOD) with concomi-
tantly increased ROS levels - again only upon irradiation
at 0.5 Gy. Since previous studies described a local dose
maximum for activation of the transcription factor NF-κB
after irradiation of EC at 0.5 Gy, the authors speculate that
increased DNA double strand breaks as well as aug-
mented NF-κB activation both result from elevated ROS
levels after irradiation at 0.5 Gy. In summary, these results
suggest that mechanisms of RT-induced DNA damage re-
sponse and immune modulation are interconnected and
follow a non-linear, discontinuous dose response relation-
ship, at least in the low and moderate dose range.
The preclinical in vitro and in vivo studies presented
in our Special Topic Immunological aspects of radiother-
apy convincingly reveal that RT can contribute to en-
hance the immunogenicity of tumor cells as well as their
in vivo microenvironment, and that RT can successfully
be combined with selected immunotherapeutic ap-
proaches for the attendance of glioblastoma, SCCHN,
NSCLC, lymphoma, and LLC model systems. In turn,
cells of the innate immune system (like monocytes, mac-
rophages, and NK cells), those connecting innate and
adaptive immunity (like DC and NKT cells), and those
of the adaptive immune system (like CD4+ and CD8+ T
cells) contribute to the outcome of RT and/or radio-
immunotherapy. Seminal evidence suggests that DNA
damage responses are linked to innate as well as adap-
tive immune mechanisms. Apart from the intended ef-
fects in terms of tumor cell death induction and the
stimulation of anti-tumor immunity this interconnection
might also influence the onset of adverse RT side effects,
including irradiation-induced pneumonitis, as well as
their subsequent resolution.
A crucial issue in the context of RT-stimulated im-
munological effects is the dose-response relationship,
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ticularly when low dose irradiation is utilized to attenu-
ate acute or chronic inflammation. In the higher dose
range, fractionated RT regimes clearly differ from abla-
tive single dose regimes with regard to the induction of
tumor cell death and the stimulation of immune cell re-
cruitment. Additionally, the p53 status, the hormone
receptor status, functional Atm/Atr signaling, and pre-
sumably many more - prima vista unrelated - character-
istics of tumor cells impact on the immunological
properties of irradiated tumor cells, including the type of
tumor cell death they undergo, the induction of NKG2D
ligands, and the stimulation of monocyte recruitment.
Hence, the major challenges for the future are to de-
fine the optimal dose of RT together with optimized
fractionation regimes and to design choreography and
chronology of combined modality strategies with selected
immunotherapeutic approaches carefully. By doing so, we
might be able to advance RT towards optimal local tumor
control with concomitant stimulation of long-lasting, sys-
temic anti-tumor immunity and simultaneous avoidance
of unwanted side effects. In this regard, RT appears to be
'a perfect match' for immunotherapy and - apart from its
prominent role in DNA damage induction - should be
considered as in situ inducer of immunogenic tumor cells.
Finally, we would like to thank all authors, who have con-
tributed to this Special Topic on emerging basic and
preclinical research as well as clinical perspectives of im-
munological aspects of radiotherapy.
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